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Abstract
Aims: Moderately hypofractionated breast irradiation has been evaluated in several prospective studies, resulting in wide acceptance of shorter treatment
protocols for postoperative breast irradiation. Reimbursement for radiation therapy varies between private and public systems and between countries,
impacting variably financial considerations in the use of hypofractionation. The aim of this study was to evaluate the financial impact of moderately hypo-
fractionated breast irradiation by reimbursement system in different countries.
Materials and methods: The study was designed by an international group of radiation oncologists. A web-questionnaire was distributed to representatives from
each country. The participants were asked to involve the financial consultant at their institution.
Results: Data from 13 countries from all populated continents were collected (Europe: Denmark, France, Italy, the Netherlands, Spain, UK; North America:
Canada, USA; South America: Brazil; Africa: South Africa; Oceania: Australia; Asia: Israel, Taiwan). Clinicians and/or departments in most of the countries
surveyed (77%) receive remuneration based on the number of fractions delivered to the patient. The financial loss per patient estimated resulting from applying
moderately hypofractionated breast irradiation instead of conventional fractionation ranged from 5e10% to 30e40%, depending on the healthcare provider.
Conclusion: Although a generalised adoption of moderately hypofractionated breast irradiation would allow for a considerable reduction in social and economic
burden, the financial loss for the healthcare providers induced by fee-for-service remuneration may be a factor in the slow uptake of these regimens. Therefore,Author for correspondence: G.N. Marta, Department of Radiation Oncology, Hospital SírioeLibane
ˇ
s, Rua Dona Adma Jafet 91, Sao PauloeSP 01308e050,
Brazil. Tel: þ55-11-33945367.
E-mail address: gustavonmarta@gmail.com (G.N. Marta).
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G.N. Marta et al. / Clinical Oncology 33 (2021) 322e330 323fee-for-service reimbursement may not be preferable for radiation oncology. We propose that an alternative system of remuneration, such as bundled payments
based on stage and diagnosis, may provide more value for all stakeholders.
 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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The burden of cancer is increasing as a result of several
factors, including an aging population. Even though there is
international variation in breast cancer incidence and
mortality between countries, breast cancer remains the
most frequent cancer and themost common cause of cancer
death in women internationally [1].
Breast cancer accounts for the highest healthcare ex-
penses in the European Union [2]. Expenses aremostly from
breast cancer medication costs. However, screening pro-
grammes, diagnostic procedures, other treatments modal-
ities and other care costs, together with the productivity
lost (e.g. time lost to the patient from work in order to
receive treatments), significantly contribute to the eco-
nomic burden posed by breast cancer [3].
In the curative setting, postoperative radiation therapy
for breast cancer has been shown in systematic reviews
and meta-analyses of prospective trials to reduce the
locoregional relapse rate and to increase survival rates
[4,5]. Previously, postoperative breast radiation therapy
was given over a period of 5e6 weeks (total radiation
therapy dose of 50e50.4 Gy in 1.8e2 Gy per fraction). In
recent decades, moderately hypofractionated breast radi-
ation therapy regimens have used slightly larger daily
radiation therapy fraction sizes (e.g. 2.5e3.0 Gy), with
reduced total dose and over a shorter period of time (e.g. 3
weeks), designed to achieving similar clinical outcomes to
conventionally fractionated regimens [6,7]. Long-term
follow-up in large randomised phase III trials supported
the safety and efficacy of the hypofractionation protocols
compared with 1.8e2 Gy fractionations [8,9]. Adoption of
hypofractionation for breast cancer can reduce the burden
of treatment, with significant implications for health
economics and services. Shorter treatment protocols
reduce the case load at radiation therapy units and of the
treating teams, thus freeing up resources for more pa-
tients. It can also decrease indirect costs associated with
patient's daily travelling and work disruptions (loss of
productivity) and reduce other unaccounted for
treatment-related costs [10].
Despite there being high-level evidence to support the
use of hypofractionation-based radiation therapy for breast
cancer, together with significant financial benefits for health
economies, it has not been adopted in many countries [11].
This might be explained because the adoption of shorter
treatment regimens in the proportionally important breast
cancer patient population substantially reduces radiation
therapy activity, which could result in a financial loss
depending on the reimbursement system. On the other hand,
the adoption of shorter treatment regimens may have asignificant beneficial impact on health economics by creating
space for other treatments and decreasing waiting times.
The aim of this study was to calculate the financial
impact of adopting moderately hypofractionated breast
radiation therapy in different reimbursement systems and
to provide data and proposals on how to overcome financial
barriers to adopting hypofractionated radiation therapy for
breast cancer patients.Materials and Methods
This studywas designed by an international consortiumof
radiation oncology experts. Data regarding costs and reim-
bursement issues related to moderately hypofractionated
postoperative radiation therapy for breast cancer patients
were collected from countries in all continents. A summary
of these data was distributed to all experts in breast cancer
care to facilitate a discussion about the use of hypofractio-
nation for different curative settings of postoperative breast
radiation. Thereafter, a web-questionnaire was designed to
collect specific and relevant data to assess current reim-
bursement systems per country. This instrument included
several variables that could be related to reimbursement
calculation. If a variable was not applicable for the reim-
bursement calculation, it was described as ‘not applicable’.
Data concerning reimbursement systems as applied in the
contributors' countries were collected. Depending on the
organisation of healthcare per country, the information is in
general valid for a healthcare region or an entire country.
The reimbursement systems and the influence of
hypofractionation-based radiation schedules on revenue
were evaluated from both public and private (when appli-
cable) practice perspectives. Basically, the two mainstream
reimbursement systems are ‘fee-for-service’ (most systems
are based on payment per fraction of radiation therapy) and
the ‘global (lump sum/fixed fee)’ method. Therefore, we
divided the observed worldwide variance of reimbursement
systems into two groups: separate fees per activity (fee-for-
service) or lumpsum for the entire treatment (fixed fee).
In the case of per fee-for-service, information about
reimbursement fees was collected for two-dimensional (ra-
diation therapy) treatment planning, three-dimensional
conformal radiation therapy planning, intensity-modulated
radiation therapy (IMRT) planning, per fractionation, per
treatment week and for on-treatment physician visits.
Information was provided by the authors of this study in
collaboration with their local institutional financial
departments or national policies. As the relative value of euro
and dollar varies by only 10%, we did not recalculate into one
single currency and assume this as unity.
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In total, data from 13 countries were collected (Europe:
Denmark, France, Italy, the Netherlands, Spain, UK; North
America: Canada, USA; South America: Brazil; Africa: South
Africa; Oceania: Australia; Asia: Israel, Taiwan). Within
Canada and Italy, where healthcare is managed on a pro-
vincial level, the provinces of Nova Scotia and Quebec, and
Tuscany and Lombardy reported data separately. The
number of fractions influenced reimbursement in most
countries (77%). The corresponding revenue loss generated
by the reduction in per-patient income from applying a
hypofractionation-based schedule ranged from 5e10% toTable 1
Basis of reimbursement and the potential influence of moderately hyp
Country Perspective Base of reimbursemen
Australia Public practice Separate fees per acti
Private Practice Separate fees per acti
Brazil Public practice Lump sum for the ent
treatment (fixed fee)
Private practice Lump sum for the ent
treatment (fixed fee)
Private practice Separate fees per acti
Canada (Quebec) Public practice Separate fees per acti
Private Practice NA
Canada (Nova Scotia) Public practice Lump sum for the ent
treatment (fixed fee)
Private Practice NA
Denmark Public practice Separate fees per acti
Private Practice NA
France Public practice Separate fees per acti
Private Practice Separate fees per acti
Israel Public practice Separate fees per acti
Private practice Separate fees per acti
Italy (Tuscany Region) Public practice Separate fees per acti
Private Practice Separate fees per acti
Italy (Lombardy) Public practice Separate fees per acti
Private Practice Separate fees per acti
The Netherlands Public practice Lump sum for the ent
treatment (fixed fee)
Private Practice NA
South Africa Public practice Lump sum for the ent
treatment (fixed fee)
Private Practice Separate fees per acti
Spain Public practice Lump sum for the ent
treatment (fixed fee)
Private practice Lump sum for the ent
treatment (fixed fee)
Taiwan Public practice Separate fees per acti
Private Practice Separate fees per acti
UK Public practice Separate fees per acti
Private Practice Separate fees per acti
USA Public practice Separate fees per acti
Private Practice Separate fees per acti
NA, not available.30e40% (Table 1). When a revenue loss occurred, most
countries (60%) reported a loss of 30e40% (Figure 1).
A variety of reimbursement systems exist in the evalu-
ated countries. From the public sector perspective, in most
countries (Australia, Canada e Quebec, Israel, Italy, Spain,
Taiwan, UK and USA), reimbursement differs based on
treatment planning technique; only three countries do
not differentiate between IMRT planning and three-
dimensional conformal radiation therapy planning
(Denmark, Canada e Nova Scotia and France). Similarly, for
all countries that have private practice, IMRT planning is
related to higher reimbursement. Tables 2 and 3 summarise
the reimbursement practice (per activity separately and perofractionated radiation schedules on revenue
t Is there an influence




by the reduction in income


































Fig 1. Decrease in remuneration generated by the reduction in per-patient reimbursement from applying a hypofractionation-based schedule
compared with conventional fractionation.
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private perspective, respectively.
Discussion
To the best of our knowledge, this is the first study
reporting the financial impact of worldwide radiation
therapy reimbursement systems on the use of moderately
hypofractionated postoperative radiation therapy for breast
cancer patients. As breast cancer treatment makes up about
25% of the activities of most radiation oncology de-
partments, a relative financial loss by introducing moderate
hypofractionation for breast cancer immediately translates
into a major reduction of overall revenues.
In general, a radiation therapy budget is expected to
make up just 5% of yearly cancer care costs and therefore
denotes less than 1% of the total healthcare budget [3,12]. To
achieve the all-purpose aims of healthcare, there are several
methods and tools that can be considered, such as quality,
availability, acceptability and accessibility and, based on
these, legislation and organisational models are created
[13]. The definition of healthcare reimbursement systems
involves the concept of the mode by which money is given
to the care provider by healthcare customers [14]; suppliers
can be institutional (e.g. hospitals), individual (e.g. physi-
cians) or both combined. Although treatment costs and
reimbursement are frequently used interchangeably to
arrange the background for financial platforms and up-
coming assets, it is essential to differentiate reimbursement,
which is the consequence of compromises between payers
and healthcare suppliers, from costs, which are related to
real resource consumption [15,16]. The form of reimburse-
ment implemented in a nation provides insight into how
the healthcare system offers remuneration for particular
treatments [14].
Assessing the costs of radiation therapy is not a simple
task and the features and structures available in each
country should be considered [16e19]. In the HealthEconomics in Radiation Oncology (HERO) - European Soci-
ety for Radiotherapy and Oncology (ESTRO) study, 52 arti-
cles were analysed regarding the type and quality of
radiation therapy cost, revealing that cost-calculation
studies from the healthcare provider's standpoint still
need a robust instrument for measuring radiation therapy
costs. The results of methodologically all-encompassing
cost studies indicate that the inadequate use of conven-
tional cost-evaluation methods combined with the
unsatisfactory data on resource inputs, has hampered
comparability across published papers [16].
The cost of radiation therapy is often associated with the
necessary investments in infrastructure and high-priced
equipment. Radiation therapy equipment capable of more
complex treatments such as IMRT require a higher capital
expenditure related to both investment and maintenance
than those capable of more basic treatments, and this cost is
reflected in the higher remuneration to providers for using
these techniques. Nevertheless, due to the labour-intensive
task of technical planning and radiation therapy treatment
delivery, the models of cost estimation show that the costs
of salaries noticeably exceed those of equipment
[10,12,20,21]. When radiation therapy complexity increases,
additional costs are incurred to allow for treatment prepa-
ration, contemplation of delivery time and quality assur-
ance [22]. It is not surprising, therefore, that radiation
therapy costs are also determined by the total treatment
period, such that reducing the number of fractions can have
a meaningful impact [3,23].
The total cost of radiation therapy includes various
components, including the costs of treatment-related ac-
tivities, hospital overheads and social costs (Figure 2). For
breast cancer patients, some cost components are the same
for all treatments; for instance, the same radiation therapy
technique is generally applied for the entire duration of the
treatment regardless of the dose schedule. It is important to
highlight that the time freed up can be used to increase the
throughput of patients and reduce waiting lists. The time
Table 2
Public practice. Reimbursement practice e per activity separately and per lump sum for the entire treatment
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2D, two dimensional; 3D-CRT, three-dimensional conformal radiation therapy; C-WBI, conventional whole-breast irradiation; HF-WBI,
hypofractionated whole-breast irradiation; IMRT, intensity-modulated radiation therapy; NA, not applicable.
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time-consuming treatment approaches, including radical
treatment for oligometastases. Thereby, the total cost di-
minishes with a reduction of the number of fractions. From
an Australian perspective [24], the financial impact of using
hypofractionated post-mastectomy radiation therapy is a
cost reduction of over $2000 per patient. Similarly, in a US
assessment, the per-case marginal reduction of the hypo-
fractionated schedule was $4297 for breast cancer patients[11]. The social-cost perspective should also be part of this
discussion. In the US context, Suh et al. [25] estimated the
costs of transportation using the average number of miles
moved per day, the average reimbursement rate per mile
and the parking costs. Using the national average hourly
wage for 55- to 64-year-old US women as a reference, the
authors calculated the number of hours spent during
treatment and displacement. Unsurprisingly, these non-
direct medical costs were evidently associated with the
Table 3
Private practice. Reimbursement practice e per activity separately and per lump sum for the entire treatment
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2D, two dimensional; 3D-CRT, three-dimensional conformal radiation therapy; C-WBI, conventional whole-breast irradiation; HF-WBI,
hypofractionated whole-breast irradiation; IMRT, intensity-modulated radiation therapy; NA, not applicable.
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shorter total treatment times were advantageous [25]. A
study from Ontario, which has a socialised healthcare sys-
tem, showed that for whole-breast irradiation, patients
were bearing 37% of the treatment cost because of the daily
commute to the hospital [26].
In addition to the evident benefit of hypofractionation
on costs [3,27], it is important to review the reimburse-
ment system in an overall evaluation of institutions before
adopting shorter schedules as practice. Konski et al. [11]
showed the consequences in terms of costs and reim-
bursement when a US radiation oncology department used
hypofractionation for most common tumours, thus
exploiting Medicaid- and Medicare-qualified unit valuesand reimbursement rates. The relative value unit for 2015
was used to establish any alterations in reimbursements.
The variation in the total number of fractions was adjusted
to measure the consequences in terms of staff time, ma-
chine capacity and workforce predictions. The results
indicated that if 100 breast cancer patients are treated
with shorter schedules, hospital-based technical billing
due to hypofractionation would be reduced by $429
699.98. The per-case marginal reduction for each physician
was 10.44 relative value units, representing a decrease of
1044 relative value units for each 100 breast cancer pa-
tients who receive hypofractionation. Hence, considering
these US-based cost calculations, an increase in hypo-
fractionation prescription over conventional fractionation
Fig 2. Costs of treatment-related activities, hospital overheads and social costs.
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partments, which will then have to deal, at least on the
short to intermediate term, with financial losses resulting
from a reduction in per-patient income in fractionation-
based reimbursement arrangements.
This study shows that although reimbursement practices
differ across public and private institutions and between
countries, the financial loss from a reduction in per-patient
income due to the use of a hypofractionation-based
schedule is substantial and quite similar across payment
systems and countries (Table 2, Figure 1). It is important to
highlight that the reimbursement information was pro-
vided by the authors of this study. Although there may be
even more variation when also taking not-evaluated med-
ical services into account, the retrieved data serve as the
basis for an overview of reimbursement amounts for each
country across public and private practices in Europe, the
Americas, Africa, Asia and Oceania. Moreover, the results of
this study are in agreement with a recent report from the
HERO-ESTRO group that analysed the reimbursement of
public health radiation therapy services in Europe [15].
Moreover, as illustrated in Tables 2 and 3, reimbursement is
not only based on the number of fractions but also on the
complexity of the technique used, wherein complex treat-
ment planning is generally associated with higher reim-
bursement fees.
Reimbursement of treatment planning and treatment
delivery may depend on a number of other factors that vary
between countries: complexity of delivery, image guidance,respiratory control, etc. The introduction of new techniques
and/or modalities in radiation oncology is most often
translated into the ‘level of complexity’. With fractionation
being the main factor in most fee-for-service systems and
other co-variables adding up to a huge number of possible
combinations, we focused solely on the effect of hypo-
fractionation. Healthcare reimbursement is adapted,
depending on the country, at intervals varying between
annually up to exceeding a decade.
The objective to provide reliable, safe and high-quality
radiation therapy while minimising both acute and late
side-effects is related to optimal treatment planning and
delivery, independent of the fractionation schedule used. By
contrast, the antiquated system of paying by fraction
number is nonsensical and counterintuitive, hampering the
introduction of evidence-based shorter therapy schedules.
Very recently, the first tumour outcome-related end point
evaluation from the FAST Forward trial was published
[28,29], which proposed a schedule of just five fractions in 1
week. If a mod If a moderately hypofractionated schedule is
replaced for many patients in the coming years by a 5
fractions in 1 week schedule, it will demand much more
robustness of RT treatment planning and delivery. These
few fractions could hence cost more per fraction (due to the
more complex verification) than conventional fractionation
andmoderate hypofractionation to plan and deliver. Thus, it
is important to propose a better remuneration system based
on complexity rather than one so heavily influenced by
fraction number.
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duce improved and optimised reimbursement and
healthcare delivery systems. Recently, scholars worldwide
have examined various delivery and payment models,
including those that are evolutions of the fee-for-service
system [30]. Optimal alternative payment systems aim at
enhancing clinical outcomes and decreasing both con-
sumption and costs. To maximise outcomes, the model
(value-based) intervention ought to be focused on
improving the equilibrium between cost and healthcare
quality. The value-based payment concept d in which
healthcare consumers and payers maintain the distribu-
tion system that is largely responsible for both costs and
quality of care d is one of the most studied models, and it
promises to have a positive impact in this framework.
However, it is important to recognise that, notwith-
standing the advances of alternative payment systems,
there is still limited evidence regarding the efficacy of
these reimbursement models; this issue requires further
debate before practical implementation [31,32].
The financial discussion of the viability of widespread
adoption of moderate hypofractionation in breast cancer
patients has special importance for countries with limited
resources [33e35]. Khan et al. [36] evaluated the impact of
shorter schedules for breast cancer patients from countries
with emerging economies and restricted radiation therapy
assets. The implementation of hypofractionation in these
emerging economies is not merely an issue of increased
cost-effectiveness but also one of improved access to quality
healthcare and enhanced patient survivorship. A shift from a
conventional schedule to hypofractionation could thereby
decrease waiting times and allow more patients to be
treated, particularly in systemswith restricted funds [37,38].
Finally, the importance of hypofractionation has perhaps
never before been clearer than in the current pandemic. The
reduction in the number of patient visits to the radiation
oncology department by using hypofractionation is partic-
ularly important, insofar as this approach limits the risk for
disease transmission for both patients and personnel, while
at the same time preventing jeopardising the outcomes of
cancer intervention [39,40]. Although our study was con-
ducted before the worldwide COVID-19 pandemic, its in-
sights are even more relevant now and for the future.
Finally, it is unethical to deny any patient access to
evidenced-based moderate breast hypofractionation based
on a potential loss of income. Out-dated reimbursement
systems need to be re-designed to facilitate implementation
of high-quality randomised trial results and reflect complex
and quality-assured modern radiation therapy.
Conclusions
Moderately hypofractionated radiation therapy schedules
are preferable for breast cancer patients, by decreasing the
daily burden linked to travel and disutility following a lower
number of treatment fractions, but similar rates of local
relapse and often reduced side-effects. Moreover, its wide-
spread adoptionwill alsobebeneficial forhealthcare systems,by reducing the workload for both healthcare providers and
infrastructure, especially when resources are limited. The
possiblefinancial loss induced by the reduction inper-patient
income due to fractionation-based reimbursement should be
compensated by an evolution of the reimbursement model
from a fee-for-service system to a bundled payment system.
In this context, the reimbursement systems should be more
adaptable based on progress in both knowledge and tech-
niques, and not remain so inert over time. We therefore
favour a change in the current fee-for-service model preva-
lent worldwide, to onewhich allows for better compensation
for increased quality in treatment planning and delivery.
The reimbursement amount could then be based on average
cost data collected from patients receiving optimal breast
radiation therapy. As reimbursement in such a model should
be independent of the type of radiation therapy planning
and the number of fractions, clinicians may be more inclined
to favour moderately hypofractionated treatment schedules
and their associated radiation therapy planning. This would
improve value for all stakeholders, including doctors,
payers and the country's healthcare system, but above all
improve the patient experience, which is paramount.Conflicts of interest
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